T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Estrogen Receptor Positive|HER2/Neu Negative|Invasive Breast Carcinoma|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Recurrent Breast Carcinoma
Interventions: DRUG: Anastrozole|DRUG: Exemestane|DRUG: Fulvestrant|DRUG: Letrozole|DRUG: Paclitaxel|BIOLOGICAL: Talimogene Laherparepvec|DRUG: Tamoxifen|DRUG: Nab paclitaxel|DRUG: Gemcitabine|DRUG: Carboplatin
Sponsor: University of California, San Francisco
Collaborators: Amgen